Benjamin P. Linas MD

Professor, Infectious Diseases

Professor, Epidemiology

771 Albany St | (617) 414-5238
belinas@bu.edu
benjamin.linas@bmc.org

Sections

Infectious Diseases

Biography

Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Websites

BU Profile

@BenjaminLinas

Boston-Providence Center for AIDS Research

NIDA Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV

Boston Medical Center Provider Profile

Harvard Prevention Policy Modeling Lab

Education

Medicine, MD, New York University School of Medicine

Clinical Evaluation/Research, MPH, Harvard School of Public Health

Economics, BA, Yale University

Publications

Published on 5/1/2025

Curtis MR, Munroe S, Biondi BE, Ciaranello AL, Linas BP, Epstein RL. Disparities in Linkage to Care Among Children With Hepatitis C Virus in the United States. Pediatrics. 2025 May 01; 155(5). PMID: 40246302.

PubMed

Published on 4/21/2025

Linas BP, Weitz M, Pramanick T, Sulkowski M, Smeaton LM, Cardoso SW, Solomon S. Health economic outcomes of a minimal monitoring approach to providing HCV therapy. Hepatol Commun. 2025 May 01; 9(5). PMID: 40257357.

PubMed

Published on 4/17/2025

Barocas JA, Aldridge A, Adkins KF, Barbosa C, Battaglia TA, Bush J, Castry M, Corry G, Clarke T, El-Bassel N, Figueroa W, Freedman DA, Freisthler B, Gibbons B, Gibson EB, Glasgow L, Harlow K, Huerta TR, Hunt T, Johnson R, Larimore E, Linas BP, Luckey JM, Montoya I, Murphy SM, Oga E, Onuoha E, Orme S, Ryan D, Schackman BR, Seiber EE, Singer M, Speer D, Starbird L, Tin Y, Villani J, Walsh SL, Watson C, Zarkin GA, McCollister K. An economic analysis of community costs incurred to implement the communities that HEAL intervention to reduce opioid overdose deaths in four states. Drug Alcohol Depend. 2025 Jul 01; 272:112671. PMID: 40311556.

PubMed

Published on 4/15/2025

Singh RP, Biondi B, Gordon SH, Linas BP, Epstein RL. Hepatitis C Virus Screening in Pregnant and Nonpregnant Women After Universal Screening Guidelines. JAMA. 2025 Apr 15; 333(15):1356-1358. PMID: 39992633.

PubMed

Published on 3/27/2025

Madushani RWMA, Wang J, Weitz M, Linas BP, White LF, Chrysanthopoulou SA. Empirical calibration of a simulation model of opioid use disorder. PLoS One. 2025; 20(3):e0310763. PMID: 40146669.

PubMed

Published on 3/10/2025

Zhu L, Havens JR, Rudolph AE, Young AM, Yazdi GE, Thompson WW, Hagan LM, Randall LM, Wang J, Earnest R, Nolen S, Linas BP, Salomon JA. Hepatitis C virus transmission among people who inject drugs in rural United States: mathematical modeling study using stochastic agent-based network simulation (AJE-00824-2024). Am J Epidemiol. 2025 Mar 10. PMID: 40069947.

PubMed

Published on 3/3/2025

Jones MA, Jones M, Mazor KM, Linas BP. Health Concerns of Youths From Historically Marginalized Communities During the Postacute Phase of COVID-19. JAMA Netw Open. 2025 Mar 03; 8(3):e250837. PMID: 40085088.

PubMed

Published on 3/1/2025

Munroe S, Schackman BR, Madkins K, Saber R, Macapagal K, Vititow J, Sweeney N, Feder NM, Benbow N, Mustanski B, Linas BP. Economic Evaluation of Delivering an Evidence-Based Online HIV Prevention Program to MSM via Direct-To-Consumer Marketing Versus Community-Based Organization Recruitment. J Acquir Immune Defic Syndr. 2025 Mar 01; 98(3):257-264. PMID: 39621530.

PubMed

Published on 2/28/2025

Torres TS, Saha PT, Smeaton L, Wimbish C, Kliemann DA, Avihingsanon A, Kityo C, Bennet JA, Van Schalkwyk M, Linas B, Nunes EP, Robbins GK, Wyles D, Naggie S, Sulkowski M, Cardoso SW, Solomon S. Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life. Qual Life Res. 2025 Feb 28. PMID: 40019678.

PubMed

Published on 2/24/2025

Epstein RL, Munroe S, Taylor LE, Duryea PR, Buzzee B, Pramanick T, Feld JJ, Baptiste D, Carroll M, Castera L, Sterling RK, Thomas A, Chan PA, Linas BP. Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study. Clin Infect Dis. 2025 Feb 24; 80(2):300-313. PMID: 39535186.

PubMed

View full list of 191 publications.